Brief: Syndax Announces FDA Approval Of Revuforj® (Revumenib), The First And Only Menin Inhibitor To Treat Adult And Pediatric Patients With Relapsed Or Refractory Acute Leukemia With A Kmt2a Translocation

Syndax Pharmaceuticals

15/11/2024 23:05

Nov 15 (Reuters) - Syndax Pharmaceuticals Inc  SNDX.O :
    * SYNDAX ANNOUNCES FDA APPROVAL OF REVUFORJ® (REVUMENIB),
THE
FIRST AND ONLY MENIN INHIBITOR TO TREAT ADULT AND PEDIATRIC
PATIENTS WITH RELAPSED OR REFRACTORY ACUTE LEUKEMIA WITH A KMT2A
TRANSLOCATION
    * SYNDAX PHARMACEUTICALS INC - REVUFORJ 110 AND 160 MG
TABLETS
EXPECTED TO BE AVAILABLE FOR ORDER IN U.S. IN NOVEMBER
    * SYNDAX PHARMACEUTICALS - 25 MG REVUFORJ TABLETS EXPECTED
TO BE
COMMERCIALLY  AVAILABLE IN LATE Q1 OR EARLY Q2 OF 2025
    * SYNDAX PHARMACEUTICALS: BEFORE COMMERCIAL AVAILABILITY OF
25 MG
TABLETS, ORAL SOLUTION OF REVUMENIB TO BE AVAILABLE THROUGH
EXPANDED ACCESS PROGRAM

Source text:  ID:nPn3NsDvKa 
Further company coverage:  SNDX.O 

 ((Reuters.Briefs@thomsonreuters.com;))